We are live on ! Find out more
TTNP

Titan Pharmaceuticals
TTNP

Delisted

TTNP was delisted on the 1st of October, 2025.

Back to rankings

47 hedge funds and large institutions have $17M invested in Titan Pharmaceuticals in 2016 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 11 increasing their positions, 3 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

866% more call options, than puts

Call options by funds: $1.18M | Put options by funds: $122K

267% more repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 3

160% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 5

21% more funds holding

Funds holding: 39 → 47 (+8)

19% more capital invested

Capital invested by funds: $14.3M → $17M (+$2.74M)

Holders
47
Holders Change
+8
Holders Change %
+20.51%
% of All Funds
1.25%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
13
Increased
11
Reduced
3
Closed
5
Calls
$1.18M
Puts
$122K
Net Calls
+$1.06M
Net Calls Change
-$545K

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$311K
2
AQR Capital Management
AQR Capital Management
Connecticut
+$272K
3
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$272K
4
AIM
Acrospire Investment Management
Illinois
+$175K
5
PMG
ProVise Management Group
Florida
+$155K

Top Sellers

Rank Fund Capital Flow
1
GS
Gagnon Securities
New York
-$340K
2
Citadel Advisors
Citadel Advisors
Florida
-$85K
3
VKH
Virtu KCG Holdings
New York
-$38.8K
4
Creative Planning
Creative Planning
Kansas
-$27K
5
Bank of New York Mellon
Bank of New York Mellon
New York
-$19.4K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$3.69M +$311K +16 +10%
BFA
2
BlackRock Fund Advisors
California
$3.02M +$136K +7 +5%
State Street
3
State Street
Massachusetts
$1.84M +$77.7K +4 +5%
Northern Trust
4
Northern Trust
Illinois
$1.18M +$58.3K +3 +6%
BIT
5
BlackRock Institutional Trust
California
$771K – – –
Geode Capital Management
6
Geode Capital Management
Massachusetts
$666K +$19.4K +1 +3%
Goldman Sachs
7
Goldman Sachs
New York
$609K +$38.8K +2 +7%
BIM
8
BlackRock Investment Management
Delaware
$420K – – –
Bank of New York Mellon
9
Bank of New York Mellon
New York
$359K -$19.4K -1 -6%
AQR Capital Management
10
AQR Capital Management
Connecticut
$305K +$272K +14 New
Dimensional Fund Advisors
11
Dimensional Fund Advisors
Texas
$299K +$272K +14 New
VKH
12
Virtu KCG Holdings
New York
$250K -$38.8K -2 -14%
California State Teachers Retirement System (CalSTRS)
13
California State Teachers Retirement System (CalSTRS)
California
$234K – – –
Bank of America
14
Bank of America
North Carolina
$222K – – –
Stifel Financial
15
Stifel Financial
Missouri
$195K – – –
AllianceBernstein
16
AllianceBernstein
Tennessee
$181K – – –
AIM
17
Acrospire Investment Management
Illinois
$181K +$175K +9 New
SO
18
STRS Ohio
Ohio
$178K +$155K +8 New
Charles Schwab
19
Charles Schwab
California
$177K – – –
TA
20
Teachers Advisors
New York
$177K – – –
California Public Employees Retirement System
21
California Public Employees Retirement System
California
$165K – – –
D.E. Shaw & Co
22
D.E. Shaw & Co
New York
$150K +$136K +7 New
Millennium Management
23
Millennium Management
New York
$146K +$136K +7 New
Susquehanna International Group
24
Susquehanna International Group
Pennsylvania
$145K +$136K +7 New
SIM
25
Spark Investment Management
New York
$141K +$77.7K +4 +133%
1
2 3

TTNP Hedge Fund Activity: Q3 2016 in Review

47 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Titan Pharmaceuticals (TTNP) for Q3 2016, worth a combined $17M — up 19% from $14.3M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new TTNP positions and 5 closed out — a net gain of 8 holders — while 11 added to existing stakes and 3 trimmed.

The largest buyer was Vanguard Group, adding an estimated $311K. The largest seller was Gagnon Securities, exiting entirely with an estimated $340K sold.

  • 47 institutional investors held Titan Pharmaceuticals (TTNP) as of Q3 2016, up from 39 in Q2 2016.
  • Funds reported $17M of Titan Pharmaceuticals stock for Q3 2016, up 19% quarter-over-quarter.
  • 13 funds opened new Titan Pharmaceuticals positions in Q3 2016 and 5 closed out, a net change of +8 holders.
  • The largest Titan Pharmaceuticals buyer in Q3 2016 was Vanguard Group, an estimated $311K added.
  • The largest Titan Pharmaceuticals seller in Q3 2016 was Gagnon Securities, an estimated $340K sold.

Based on aggregated 13F filings for Q3 2016.